Strides Pharma Science Limited’s shares rose 5% following the release of its Q3 FY25 financial results, showcasing robust year-on-year (YoY) growth and a strong profit recovery. As of 1:43 PM, the shares were trading 4.72% higher at Rs 637.65.
The company’s revenue from operations reached Rs 1,154 crore, marking a 15% increase compared to Rs 1,006 crore in Q3 FY24. Despite a slight 1% sequential dip from Q2 FY25’s Rs 1,167 crore, Strides Pharma’s top-line growth remained impressive.
Total income for the quarter stood at Rs 1,159 crore, up from Rs 1,014 crore in the same period last year. Expenses rose by 6% YoY to Rs 1,044 crore, driven primarily by higher material costs and operating expenses. Despite these challenges, Strides Pharma’s profit before tax surged to Rs 112 crore, a significant recovery from a loss of Rs 22 crore in Q3 FY24. The company’s net profit after tax shot up to Rs 90 crore, compared to Rs 5 crore in the previous year and Rs 72 crore in Q2 FY25.
Strides Pharma’s shares opened at ₹617.85, reaching a high of ₹645.00 and a low of ₹577.05 today. The stock’s 52-week high stands at ₹804.00, while its 52-week low is ₹324.70.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
